论文部分内容阅读
目的:观察新辅助化疗联合曲妥珠单抗对HER-2过表达乳腺癌的临床疗效。方法:39例HER-2过表达的乳腺癌患者,均采用多西他赛及卡铂新辅助化疗联合曲妥珠单抗治疗,6个周期后观察疗效并对乳腺癌组织中雌激素受体(ER)表达状态与病理完全缓解(pCR)率之间行单因素分析。结果:39例患者总有效率(OR)为94.9%(37/39);其中临床完全缓解(cCR)26例(66.7%),部分缓解(PR)11例(28.2%),疾病稳定(SD)2例(5.1%),无疾病进展(PD)病例。病理完全缓解(pCR)27例(69.2%)。单因素分析显示,ER阴性组的pCR率为82.4%,ER阳性组为59.1%。结论:在HER-2过表达乳腺癌的新辅助化疗中,多西他赛及卡铂联合曲妥珠单抗疗效良好,且ER受体阴性患者可获较高的缓解率。
Objective: To observe the clinical efficacy of neoadjuvant chemotherapy combined with trastuzumab on HER-2 overexpression in breast cancer. Methods: Thirty-nine patients with HER-2-overexpressing breast cancer were treated with docetaxel and neoadjuvant chemotherapy combined with trastuzumab. After 6 cycles, the effect of estrogen receptor (ER) expression and pathological complete remission (pCR) rate between the single-factor analysis. Results: The total effective rate (OR) of 39 patients was 94.9% (37/39). Among them, 26 patients (66.7%) had clinical complete response (CR), 11 patients (28.2% ) 2 cases (5.1%), no disease progression (PD) cases. Pathologic complete remission (pCR) in 27 cases (69.2%). Univariate analysis showed that the pCR rate was 82.4% in ER-negative group and 59.1% in ER-positive group. Conclusion: Docetaxel and carboplatin combined with trastuzumab are effective in neoadjuvant chemotherapy for HER-2-overexpressing breast cancer, and patients with ER-negative tumors have a higher response rate.